Vertex Pharmaceuticals Q3 2026: Guidance Raised, Nephrology Franchise Next
As seen on the 24/7 Wall St. homepage on November 2, 2026.
The beat was narrow, but management raised full-year revenue guidance to $13.15 billion to $13.25 billion as CASGEVY, JOURNAVX and newly acquired PALSONIFY start carrying weight beyond cystic fibrosis. An FDA decision on povetacicept in IgA nephropathy lands November 30, which would make nephrology the fifth commercial franchise.
Continue ReadingShow less
Vertex Pharmaceuticals lifted full-year guidance to $13.15 billion to $13.25 billion on third-quarter 2026 revenue of $3.44 billion, with adjusted EPS of $4.76 in line with estimates.
Growth is broadening beyond cystic fibrosis, with ALYFTREK adding $706 million and newer launches in gene therapy, pain and endocrinology now contributing revenue.
GAAP diluted EPS of $2.56 reflects acquisition-related costs from the Crinetics deal, and investors looking past the integration noise are watching whether PALSONIFY reaches its guided full-year range.
Sponsored
An FDA decision on povetacicept in IgA nephropathy carries a PDUFA date of November 30, 2026. CEO Reshma Kewalramani said the company is well positioned to establish nephrology as its fifth commercial franchise if the approval lands.
The guidance raise matters more than the narrow quarterly beat as the November 30 nephrology catalyst approaches.
Mentioned: VRTX